Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Incidence of active tuberculosis after 1-month isoniazid + rifapentine in latent tuberculosis infection among end-stage kidney disease patients awaiting kidney transplant
TCTR20211213004Not yet recruiting
- Sponsor
- Chulalongkorn University
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of isoniazid and rifapentine in Tuberculosis (TB), sponsored by Chulalongkorn University. Primary endpoint: Incidence of active tuberculosis. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
isoniazidrifapentine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on TCTR20211213004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20211213004.